HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Studies On Treating COVID-19 Inflammation And Migraines Also Weigh Efficacy Of Remote Trials

Heartburn Drug Famotidine Tested With COVID Patients, Nestle Keto Supplement For Migraines

Executive Summary

Preliminary data from Cold Springs Harbor Laboratory study suggest famotidine could mitigate inflammatory symptoms of COVID-19 in adults. Research sponsored by Nestle Health Science in Canada also points to remote studies likely to continue after emerging as a pandemic innovation.

You may also be interested in...



Tylenol Leads OTC Acetaminophen Sales Surge After Ibuprofen Scare During Pandemic – IRI

J&J leads sales growth in OTC pain relief and allergy categories in 2020 as its brands benefited from competing products’ problems and COVID-19’s impact of consumer habits. IRI reveals winning brands that kept a focus on maintaining health in 2020.

Warning Confirms Some Supplement GMP Violations Remain Common In US

An Oregon factory’s citations received by the FDA are among the most common violations the agency finds during inspections, ORA Office of Human and Animal Food Operations deputy director said.

First Recalls, Now Investors' Concerns Over Ranitidine Litigation Take Pharmas For Wild Ride

Host of complaints in US courts, seeking damages or alleging ranitidine caused various cancers, followed FDA’s 2020 findings of NDMA levels exceeding allowable limits in some samples provoked  Litigation is starting to come to trial, the first set for 22 August in Illinois and a bellwether case due to begin in California in February 2023.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS152229

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel